The DOI matches its Crossref record; 44 of the 44 references it cites were found in a registry or an index.
Targeted genome editing in human repopulating haematopoietic stem cells
Open accessAbstract
Targeted genome editing by artificial nucleases has brought the goal of site-specific transgene integration and gene correction within the reach of gene therapy. However, its application to long-term repopulating haematopoietic stem cells (HSCs) has remained elusive. Here we show that poor permissiveness to gene transfer and limited proficiency of the homology-directed DNA repair pathway constrain gene targeting in human HSCs. By tailoring delivery platforms and culture conditions we overcame these barriers and provide stringent evidence of targeted integration in human HSCs by long-term multilineage repopulation of transplanted mice. We demonstrate the therapeutic potential of our strategy by targeting a corrective complementary DNA into the IL2RG gene of HSCs from healthy donors and a subject with X-linked severe combined immunodeficiency (SCID-X1). Gene-edited HSCs sustained normal haematopoiesis and gave rise to functional lymphoid cells that possess a selective growth advantage over those carrying disruptive IL2RG mutations. These results open up new avenues for treating SCID-X1 and other diseases.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Nevertheless, the HDR pathway is not highly active in human cells, thus strongly limiting the clinical efficacy of this application23,24.”
From Allele specific repair of splicing mutations in cystic fibrosis through AsCas12a genome editing (2019) · cites this paper as [24]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The Sequence Alignment/Map format and SAMtools
Li, H., Handsaker, B., Wysoker, A., Fennell, T., Ruan, J., Homer, N., Marth, G., Abecasis, G., Durbin, R., & 1000 Genome Project Data Processing Subgroup (2009) · Bioinformatics · doi:10.1093/bioinformatics/btp352 · Cited by 62,041
Fast and accurate short read alignment with Burrows-Wheeler transform
Li, H., & Durbin, R. (2009) · Bioinformatics · doi:10.1093/bioinformatics/btp324 · Cited by 58,607
Clustal W and Clustal X version 2.0
Larkin, M., Blackshields, G., Brown, N. P., Chenna, R., McGettigan, P., McWilliam, H., Valentin, F., Wallace, I. M., Wilm, A., López, R., et al. (2007) · Bioinformatics · doi:10.1093/bioinformatics/btm404 · Cited by 28,598
The DNA Damage Response: Making It Safe to Play with Knives
Ciccia, A., & Elledge, S. J. (2010) · Molecular Cell · doi:10.1016/j.molcel.2010.09.019 · Cited by 4,368
CRISPR-Cas systems for editing, regulating and targeting genomes
Sander, J. D., & Joung, J. K. (2014) · Nature Biotechnology · doi:10.1038/nbt.2842 · Cited by 3,153
Genome editing with engineered zinc finger nucleases
Urnov, F. D., Rebar, E. J., Holmes, M. C., Zhang, H. S., & Gregory, P. D. (2010) · Nature Reviews Genetics · doi:10.1038/nrg2842 · Cited by 2,285
Self-citationA human memory T cell subset with stem cell–like properties
Gattinoni, L., Lugli, E., Ji, Y., Pos, Z., Paulos, C. M., Quigley, M. F., Almeida, J. R., Gostick, E., Yu, Z., Carpenito, C., et al. (2011) · Nature Medicine · doi:10.1038/nm.2446 · Cited by 1,974
TALENs: A widely applicable technology for targeted genome editing
Joung, J. K., & Sander, J. D. (2013) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm3486 · Cited by 1,650 · cited 1×
“Artificial endonucleases, such as Zinc Finger Nucleases (ZFNs) 11 , Transcription Activator-Like Effector Nucleases (TALENs) 12 , and RNA-guided nucleases (CRISPR/Cas) 13 brought the possibility of gene targeting within the reach of gene therapy 14,15 .”
Highly efficient endogenous human gene correction using designed zinc-finger nucleases
Urnov, F. D., Miller, J. C., Lee, Y.-L., Beausejour, C. M., Rock, J. M., Augustus, S., Jamieson, A. C., Porteus, M. H., Gregory, P. D., & Holmes, M. C. (2005) · Nature · doi:10.1038/nature03556 · Cited by 1,642
Self-citationHematopoietic Stem Cell Gene Therapy with a Lentiviral Vector in X-Linked Adrenoleukodystrophy
Cartier, N., Hacein-Bey-Abina, S., Bartholomae, C. C., Veres, G., Schmidt, M., Kutschera, I., Vidaud, M., Abel, U., Dal-Cortivo, L., Caccavelli, L., et al. (2009) · Science · doi:10.1126/science.1171242 · Cited by 1,508 · cited 1×
“Hematopoietic Stem Cells (HSC)-based gene therapy has provided therapeutic benefit in primary immunodeficiencies 1,2 , thalassemia 3 and leukodystrophies 4,5 .”
Flagged first, then by citations
Cited by
Sorted by citations
Items 101–200 of 561
Dastidar, S., Ardui, S., Singh, K., Majumdar, D., Nair, N., Fu, Y., Reyon, D., Samara-Kuko, E., Gerli, M., Klein, A. F., et al. (2018) · Nucleic Acids Research · doi:10.1093/nar/gky548 · Cited by 104
Lomova, A., Clark, D. N., Campo-Fernández, B., Flores, C., Kaufman, M. L., Fitz‐Gibbon, S. T., Wang, X., Miyahira, E., Brown, D., DeWitt, M. A., et al. (2018) · Stem Cells · doi:10.1002/stem.2935 · Cited by 97
Crippa, S., & Bernardo, M. E. (2018) · HemaSphere · doi:10.1097/hs9.0000000000000151 · Cited by 94
Neurofibromin and suppression of tumorigenesis: beyond the GAP
Mo, J., Moye, S. L., McKay, R. M., & Le, L. Q. (2022) · Oncogene · doi:10.1038/s41388-021-02156-y · Cited by 95
CRISPR/Cas9-based genetic correction for recessive dystrophic epidermolysis bullosa
Webber, B. R., Osborn, M. J., McElroy, A. N., Twaroski, K., Lonetree, C.-L., DeFeo, A. P., Xia, L., Eide, C. R., Lees, C. J., McElmurry, R. T., et al. (2016) · npj Regenerative Medicine · doi:10.1038/npjregenmed.2016.14 · Cited by 98
The Promise and the Hope of Gene Therapy
Papanikolaou, E., & Bosio, A. (2021) · Frontiers in Genome Editing · doi:10.3389/fgeed.2021.618346 · Cited by 101
Zhu, H., & Liang, C. (2019) · Bioinformatics · doi:10.1093/bioinformatics/bty1061 · Cited by 88
Thalassemia 2016: Modern medicine battles an ancient disease
Rund, D. G. (2015) · American Journal of Hematology · doi:10.1002/ajh.24231 · Cited by 89
Roman‐Rodriguez, F. J., Ugalde, L., Alvarez, L. A., Díez, B., Ramírez, M. J., Risueño, C., Cortón, M., Bogliolo, M., Bernal, S., March, F., et al. (2019) · Cell stem cell · doi:10.1016/j.stem.2019.08.016 · Cited by 93
Allele specific repair of splicing mutations in cystic fibrosis through AsCas12a genome editing
Maule, G., Casini, A., Montagna, C., Ramalho, A. S., De Boeck, K., Debyser, Z., Carlon, M. S., Petris, G., & Cereseto, A. (2019) · Nature Communications · doi:10.1038/s41467-019-11454-9 · Cited by 86
Shin, J. J., Schröder, M., Caiado, F., Wyman, S. K., Bray, N., Bordi, M., DeWitt, M. A., Vu, J. T., Kim, W., Hockemeyer, D. F., et al. (2020) · Cell Reports · doi:10.1016/j.celrep.2020.108093 · Cited by 87
Targeted regulation of transcription in primary cells using CRISPRa and CRISPRiPreprint
Jensen, T. I., Mikkelsen, N. S., Gao, Z., Foßelteder, J., Pabst, G., Axelgaard, E., Laustsen, A., König, S., Reinisch, A., & Bak, R. O. (2021) · Genome Research · doi:10.1101/gr.275607.121 · Cited by 92
Mastaglio, S., Genovese, P., Magnani, Z. I., Ruggiero, E., Landoni, E., Camisa, B., Schiroli, G., Provasi, E., Lombardo, A., Reik, A., et al. (2017) · Blood · doi:10.1182/blood-2016-08-732636 · Cited by 85
Self-citationGenome editing in crop improvement: Present scenario and future prospects
Miglani, G. S. (2017) · Journal of Crop Improvement · doi:10.1080/15427528.2017.1333192 · Cited by 86
Pavani, G., Fabiano, A., Laurent, M., Amor, F., Cantelli, E., Chalumeau, A., Maule, G., Tachtsidi, A., Concordet, J., Cereseto, A., et al. (2021) · Blood Advances · doi:10.1182/bloodadvances.2020001996 · Cited by 88
Cell and Gene Therapy for the Beta-Thalassemias: Advances and Prospects
Mansilla-Soto, J., Riviere, I., Boulad, F., & Sadelain, M. (2016) · Human Gene Therapy · doi:10.1089/hum.2016.037 · Cited by 83
The European Hematology Association Roadmap for European Hematology Research: a consensus document
Engert, A., Balduini, C., Brand, A., Coiffier, B., Cordonnier, C., Dohner, H., de Wit, T. D., Eichinger, S., Fibbe, W., Green, T., et al. (2016) · Haematologica · doi:10.3324/haematol.2015.136739 · Cited by 81
Editing aberrant splice sites efficiently restores β-globin expression in β-thalassemia
Xu, S., Luk, K., Yao, Q., Shen, A. H., Zeng, J., Wu, Y., Luo, H., Brendel, C., Pinello, L., Chui, D. H. K., et al. (2019) · Blood · doi:10.1182/blood-2019-01-895094 · Cited by 81
Arts, P., Simons, A., AlZahrani, M., Yılmaz, E., AlIdrissi, E., van Aerde, K., Alenezi, N., Alghamdi, H. A., AlJubab, H., Al‐Hussaini, A. A., et al. (2019) · Genome Medicine · doi:10.1186/s13073-019-0649-3 · Cited by 80
Clinical Applications of Gene Therapy for Primary Immunodeficiencies
Cicalese, M. P., & Aiuti, A. (2015) · Human Gene Therapy · doi:10.1089/hum.2015.047 · Cited by 80
The clinical potential of gene editing as a tool to engineer cell‐based therapeutics
Ashmore‐Harris, C., & Fruhwirth, G. O. (2020) · Clinical and Translational Medicine · doi:10.1186/s40169-020-0268-z · Cited by 79
In vivo HSC prime editing rescues Sickle Cell Disease in a mouse model
Li, C. L., Georgakopoulou, A., Newby, G. A., Chen, P. J., Everette, K. A., Paschoudi, K., Vlachaki, E., Gil, S., Anderson, A. K., Koob, T., et al. (2023) · Blood · doi:10.1182/blood.2022018252 · Cited by 88
Dreyer, A.-K., Hoffmann, D., Lachmann, N., Ackermann, M., Steinemann, D., Timm, B., Siler, U., Reichenbach, J., Grez, M., Moritz, T., et al. (2015) · Biomaterials · doi:10.1016/j.biomaterials.2015.07.057 · Cited by 75
Evolving Gene Therapy in Primary Immunodeficiency
Thrasher, A. J., & Williams, D. A. (2017) · Molecular Therapy · doi:10.1016/j.ymthe.2017.03.018 · Cited by 77
Principles of and strategies for germline gene therapy
Wolf, D. P., Mitalipov, P. A., & Mitalipov, S. M. (2019) · Nature Medicine · doi:10.1038/s41591-019-0473-8 · Cited by 75
The clinical applications of genome editing in HIV
Wang, C. X., & Cannon, P. M. (2016) · Blood · doi:10.1182/blood-2016-01-678144 · Cited by 74
Merling, R. K., Sweeney, C. L., Chu, J., Bodansky, A., Choi, U., Priel, D. L., Kuhns, D. B., Wang, H., Vasilevsky, S., Ravin, S. S. D., et al. (2014) · Molecular Therapy · doi:10.1038/mt.2014.195 · Cited by 72
Heffner, G. C., Bonner, M. A., Christiansen, L., Pierciey, F. J., Campbell, D., Smurnyy, Y. D., Zhang, W., Hamel, A., Shaw, S., Lewis, G., et al. (2017) · Molecular Therapy · doi:10.1016/j.ymthe.2017.09.025 · Cited by 79
Self-citationCure for thalassemia major – from allogeneic hematopoietic stem cell transplantation to gene therapy
Srivastava, A., & Velayudhan, S. R. (2016) · Haematologica · doi:10.3324/haematol.2015.141200 · Cited by 73
Genome engineering: a new approach to gene therapy for neuromuscular disorders
Nelson, C. E., Robinson-Hamm, J. N., & Gersbach, C. A. (2017) · Nature Reviews Neurology · doi:10.1038/nrneurol.2017.126 · Cited by 73
Li, C., Psatha, N., Gil, S., Wang, H., Papayannopoulou, T., & Lieber, A. (2018) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2018.04.008 · Cited by 69
Lymphoid Regeneration from Gene-Corrected SCID-X1 Subject-Derived iPSCs
Menon, T., Firth, A. L., Scripture-Adams, D. D., Galić, Z., Qualls, S. J., Gilmore, W. B., Ke, E., Singer, O., Anderson, L., Bornzin, A. R., et al. (2015) · Cell stem cell · doi:10.1016/j.stem.2015.02.005 · Cited by 71
Ravi, N. S., Wienert, B., Wyman, S. K., Bell, H. W., George, A., Mahalingam, G., Vu, J. T., Prasad, K. M., Bandlamudi, B. P., Devaraju, N., et al. (2022) · eLife · doi:10.7554/elife.65421 · Cited by 70
Genetic engineering meets hematopoietic stem cell biology for next-generation gene therapy
Ferrari, S., Valeri, E., Conti, A., Scala, S., Aprile, A., Micco, R. D., Kajaste‐Rudnitski, A., Montini, E., Ferrari, G., Aiuti, A., et al. (2023) · Cell stem cell · doi:10.1016/j.stem.2023.04.014 · Cited by 75
Self-citationTowards a new era in medicine: therapeutic genome editing
Porteus, M. H. (2015) · Genome Biology · doi:10.1186/s13059-015-0859-y · Cited by 69
Crippa, S., Rossella, V., Aprile, A., Silvestri, L., Rivis, S., Scaramuzza, S., Pirroni, S., Avanzini, M. A., Ricci, L. B., Hernández, R. J., et al. (2019) · Journal of Clinical Investigation · doi:10.1172/jci123191 · Cited by 67
Khosravi, M. A., Abbasalipour, M., Concordet, J., Berg, J. V., Zeinali, S., Arashkia, A., Azadmanesh, K., Buch, T., & Karimipoor, M. (2019) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2019.04.042 · Cited by 71
Schmiderer, L., Subramaniam, A., Žemaitis, K., Bäckström, A., Yudovich, D., Soboleva, S., Galeev, R., Prinz, C. N., Larsson, J., & Hjort, M. (2020) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2001367117 · Cited by 72
Immunological barriers to haematopoietic stem cell gene therapy
Charlesworth, C. T., Hsu, I., Wilkinson, A. C., & Nakauchi, H. (2022) · Nature reviews. Immunology · doi:10.1038/s41577-022-00698-0 · Cited by 71
Izmiryan, A., Ganier, C., Bovolenta, M., Schmitt, A., Mavilio, F., & Hovnanian, A. (2018) · Molecular Therapy Nucleic Acids · doi:10.1016/j.omtn.2018.06.008 · Cited by 68
Rolling microneedle electrode array (RoMEA) empowered nucleic acid delivery and cancer immunotherapy
Yang, T., Huang, D., Li, C., Zhao, D., Li, J., Zhang, M., Chen, Y., Wang, Q., Liang, Z., Liang, X., et al. (2020) · Nano Today · doi:10.1016/j.nantod.2020.101017 · Cited by 68
Peterson, C. W., Wang, J., Norman, K. K., Norgaard, Z. K., Humbert, O., Tse, C. K., Yan, J. J., Trimble, R. G., Shivak, D. A., Rebar, E. J., et al. (2016) · Blood · doi:10.1182/blood-2015-09-672337 · Cited by 68
Self-citationGenetic manipulations in crops: Challenges and opportunities
Ahmad, N., & Mukhtar, Z. (2017) · Genomics · doi:10.1016/j.ygeno.2017.07.007 · Cited by 67
Suzuki, K., Yamamoto, M., Hernández‐Benítez, R., Li, Z., Wei, C., Soligalla, R. D., Aizawa, E., Hatanaka, F., Kurita, M., Reddy, P., et al. (2019) · Cell Research · doi:10.1038/s41422-019-0213-0 · Cited by 69
Evolving AAV-delivered therapeutics towards ultimate cures
He, X., Urip, B. A., Zhang, Z., Ngan, C. C., & Feng, B. (2021) · Journal of Molecular Medicine · doi:10.1007/s00109-020-02034-2 · Cited by 70
Digital PCR to assess gene-editing frequencies (GEF-dPCR) mediated by designer nucleases
Mock, U., Hauber, I., & Fehse, B. (2016) · Nature Protocols · doi:10.1038/nprot.2016.027 · Cited by 70
IPEX syndrome: genetics and treatment options
Ben-Skowronek, I. (2021) · Genes · doi:10.3390/genes12030323 · Cited by 64
RAG gene defects at the verge of immunodeficiency and immune dysregulation
VILLA, A. M., & Notarangelo, L. D. (2018) · Immunological Reviews · doi:10.1111/imr.12713 · Cited by 69
Rare Opportunities: CRISPR/Cas-Based Therapy Development for Rare Genetic Diseases
Papasavva, P. L., Kleanthous, M., & Lederer, C. W. (2019) · Molecular Diagnosis & Therapy · doi:10.1007/s40291-019-00392-3 · Cited by 65
Dever, D. P., & Porteus, M. H. (2017) · Current Opinion in Hematology · doi:10.1097/moh.0000000000000385 · Cited by 62
Recent trends in the gene therapy of β-thalassemia
Gambari, R., Finotti, A., Breda, L., Lederer, C. W., Bianchi, N., Zuccato, C., Klenathous, M., & Rivella, S. (2015) · Journal of Blood Medicine · doi:10.2147/jbm.s46256 · Cited by 80
Benati, D., Miselli, F., Cocchiarella, F., Patrizi, C., Carretero, M., Baldassarri, S., Ammendola, V., Has, C., Colloca, S., Río, M. D., et al. (2018) · Molecular Therapy · doi:10.1016/j.ymthe.2018.07.024 · Cited by 64
Gene therapy for primary immunodeficiencies
Fischer, A., Hacein‐Bey‐Abina, S., Touzot, F., & Cavazzana, M. (2015) · Clinical Genetics · doi:10.1111/cge.12576 · Cited by 65
Improved Cell-Penetrating Zinc-Finger Nuclease Proteins for Precision Genome Engineering
Liu, J., Gaj, T., Wallen, M. C., & Barbas, C. F. (2015) · Molecular Therapy — Nucleic Acids · doi:10.1038/mtna.2015.6 · Cited by 61
MLL leukemia induction by genome editing of human CD34+ hematopoietic cells
Buechele, C., Breese, E. H., Schneidawind, D., Lin, C.-H., Jeong, J., Duque-Afonso, J., Wong, S. H. K., Smith, K. S., Negrin, R. S., Porteus, M., et al. (2015) · Blood · doi:10.1182/blood-2015-05-646398 · Cited by 60
Therapeutic gene editing in CD34+ hematopoietic progenitors from Fanconi anemia patients
Díez, B., Genovese, P., Roman‐Rodriguez, F. J., Alvarez, L. A., Schiroli, G., Ugalde, L., Rodríguez, S., Sevilla, J., de Heredia, C. D., Holmes, M. C., et al. (2017) · EMBO Molecular Medicine · doi:10.15252/emmm.201707540 · Cited by 59
Self-citationGene Therapy for Hemoglobinopathies
Cavazzana, M., & Mavilio, F. (2018) · Human Gene Therapy · doi:10.1089/hum.2018.122 · Cited by 63
Lysosomal storage disease: Gene therapy on both sides of the blood–brain barrier
Aronovich, E. L., & Hackett, P. B. (2014) · Molecular Genetics and Metabolism · doi:10.1016/j.ymgme.2014.09.011 · Cited by 63
Saydaminova, K., Ye, X., Wang, H., Richter, M., Ho, M., Chen, H., Xu, N., Kim, J., Papapetrou, E. P., Holmes, M. C., et al. (2015) · Molecular Therapy — Methods & Clinical Development · doi:10.1038/mtm.2014.57 · Cited by 57
Self-citationCRISPR-Cas9: a promising tool for gene editing on induced pluripotent stem cells
Kim, E. J., Kang, K. H., & Ju, J. H. (2017) · The Korean Journal of Internal Medicine · doi:10.3904/kjim.2016.198 · Cited by 58
Getting more for your marrow: Boosting hematopoietic stem cell numbers with PGE2
Hagedorn, E. J., Durand, E. M., Fast, E. M., & Zon, L. I. (2014) · Experimental Cell Research · doi:10.1016/j.yexcr.2014.07.030 · Cited by 56
Leiding, J. W., & Forbes, L. R. (2019) · The Journal of Allergy and Clinical Immunology In Practice · doi:10.1016/j.jaip.2018.12.017 · Cited by 56
Molecular mechanisms, off‐target activities, and clinical potentials of genome editing systems
Zheng, N., Li, L., & Wang, X. (2020) · Clinical and Translational Medicine · doi:10.1002/ctm2.34 · Cited by 59
Gene Therapy Approaches to Hemoglobinopathies
Ferrari, G., Cavazzana, M., & Mavilio, F. (2017) · Hematology/Oncology Clinics of North America · doi:10.1016/j.hoc.2017.06.010 · Cited by 56
Gene Editing of Human Hematopoietic Stem and Progenitor Cells: Promise and Potential Hurdles
Yu, K., Natanson, H., & Dunbar, C. E. (2016) · Human Gene Therapy · doi:10.1089/hum.2016.107 · Cited by 59
Flores, C., Mojadidi, M., Phillips, J., Kuo, C. Y., Lai, S. Y., Lill, G. R., Cooper, A. R., Kaufman, M. L., Urbinati, F., Wang, X., et al. (2016) · Molecular Therapy — Nucleic Acids · doi:10.1038/mtna.2016.52 · Cited by 53
Gene Therapy For Beta-Thalassemia: Updated Perspectives
Karponi, G., & Ζώγας, Ν. (2019) · The Application of Clinical Genetics · doi:10.2147/tacg.s178546 · Cited by 57
Vavassori, V., Mercuri, E., Marcovecchio, G. E., Castiello, M. C., Schiroli, G., Albano, L., Margulies, C. M., Buquicchio, F. A., Fontana, E., Beretta, S., et al. (2021) · EMBO Molecular Medicine · doi:10.15252/emmm.202013545 · Cited by 52
Self-citationGene therapy for inborn errors of immunity: past, present and future
Fischer, A. (2022) · Nature reviews. Immunology · doi:10.1038/s41577-022-00800-6 · Cited by 54
Karponi, G., Psatha, N., Lederer, C. W., Adair, J. E., Zervou, F., Ζώγας, Ν., Kleanthous, M., Tsatalas, C., Anagnostopoulos, Α., Sadelain, M., et al. (2015) · Blood · doi:10.1182/blood-2015-03-629618 · Cited by 52
Gene therapy for monogenic disorders of the bone marrow
Ghosh, S., Thrasher, A. J., & Gaspar, H. B. (2015) · British Journal of Haematology · doi:10.1111/bjh.13520 · Cited by 53
Hematopoietic Stem Cells in Regenerative Medicine: Astray or on the Path?
Müller, A. M., Huppertz, S., & Henschler, R. (2016) · Transfusion Medicine and Hemotherapy · doi:10.1159/000447748 · Cited by 55
Tian, H., Luo, J., Zhang, Z., Wu, J., Zhang, T., Busato, S., Huang, L., Song, N., & Bionaz, M. (2018) · Journal of Agricultural and Food Chemistry · doi:10.1021/acs.jafc.8b03545 · Cited by 51
CRISPR/Cas system: An emerging technology in stem cell research
Valenti, M. T., Serena, M., Carbonare, L. D., & Zipeto, D. (2019) · World Journal of Stem Cells · doi:10.4252/wjsc.v11.i11.937 · Cited by 54
Gutiérrez-Guerrero, A., Abrey-Recalde, M. J., Mangeot, P. E., Costa, C., Bernadin, O., Perian, S., Fusil, F., Froment, G., Martinez-Turtos, A., Krug, A., et al. (2021) · Frontiers in Genome Editing · doi:10.3389/fgeed.2021.604371 · Cited by 59
Applications of Genome Editing Technology in Animal Disease Modeling and Gene Therapy
Li, Q., Qin, Z., Wang, Q., Xu, T., Yang, Y., & He, Z. (2019) · Computational and Structural Biotechnology Journal · doi:10.1016/j.csbj.2019.05.006 · Cited by 52
Gene-edited pseudogene resurrection corrects p47phox-deficient chronic granulomatous disease
Merling, R. K., Kuhns, D. B., Sweeney, C. L., Wu, X., Burkett, S. S., Chu, J., Lee, J. S., Koontz, S. M., Pasquale, G. D., Afione, S. A., et al. (2016) · Blood Advances · doi:10.1182/bloodadvances.2016001214 · Cited by 50
Wu, J., Wang, M., Yang, X. W., Yi, C., Jiang, J. D., Yu, Y., & Ye, H. (2020) · Nature Communications · doi:10.1038/s41467-020-17530-9 · Cited by 50
Sweeney, C. L., Pavel-Dinu, M., Choi, U., Brault, J., Liu, T., Koontz, S. M., Li, L., Theobald, N., Lee, J., Bello, E. A., et al. (2021) · Gene Therapy · doi:10.1038/s41434-021-00251-z · Cited by 51
A single epidermal stem cell strategy for safe ex vivo gene therapy
Lathion, S., Rochat, A., Knott, G. W., Recchia, A., Martinet, D., Benmohammed, S., Grasset, N., Zaffalon, A., Schmutz, N. B., Savioz-Dayer, E., et al. (2015) · EMBO Molecular Medicine · doi:10.15252/emmm.201404353 · Cited by 49
Gene Editing of Hematopoietic Stem Cells: Hopes and Hurdles Toward Clinical Translation
Ferrari, S., Vavassori, V., Canarutto, D., Jacob, A., Castiello, M. C., Omer, A., & Genovese, P. (2021) · Frontiers in Genome Editing · doi:10.3389/fgeed.2021.618378 · Cited by 52
Self-citationCRISPR-Cas9 to induce fetal hemoglobin for the treatment of sickle cell disease
Demirci, S., Leonard, A. K., Essawi, K., & Tisdale, J. F. (2021) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2021.09.010 · Cited by 56
Gutiérrez-Guerrero, A., Sánchez-Hernández, S., Galvani, G., Pinedo-Gomez, J., Martín-Guerra, R., Sánchez‐Gilabert, A., Aguilar-González, A., Cobo, M., Gregory, P. D., Holmes, M. C., et al. (2017) · Human Gene Therapy · doi:10.1089/hum.2017.047 · Cited by 50
Self-citationRecent advances in genome editing of stem cells for drug discovery and therapeutic application
Lee, J., Bayarsaikhan, D., Bayarsaikhan, G., Kim, J., Schwarzbach, E., & Lee, B. (2020) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2020.107501 · Cited by 48
Siegner, S. M., Ugalde, L., Clemens, A., García‐García, L., Bueren, J. A., Río, P., Karasu, M. E., & Corn, J. E. (2022) · Nature Communications · doi:10.1038/s41467-022-34479-z · Cited by 51
Li, C., Mishra, A., Gil, S., Wang, M., Georgakopoulou, A., Papayannopoulou, T., Hawkins, R. D., & Lieber, A. (2019) · Molecular Therapy · doi:10.1016/j.ymthe.2019.08.006 · Cited by 46
Programmable Molecular Scissors: Applications of a New Tool for Genome Editing in Biotech
Saha, S. K., Saikot, F. K., Rahman, M. S., Jamal, M. A. H. M., Rahman, S. M. K., Islam, S. M. R., & Kim, K. (2018) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2018.11.016 · Cited by 48
Blanco, E., Izotova, N., Booth, C., & Thrasher, A. J. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.608653 · Cited by 45
Therapy Development by Genome Editing of Hematopoietic Stem Cells
Koniali, L., Lederer, C. W., & Kleanthous, M. (2021) · Cells · doi:10.3390/cells10061492 · Cited by 50
Chen, C., Li, X., Ge, G., Liu, J., Biju, K. C., Laing, S. D., Qian, Y., Ballard, C., He, Z., Masliah, E., et al. (2018) · Scientific Reports · doi:10.1038/s41598-018-23795-4 · Cited by 44
Gardner, C. L., Pavel-Dinu, M., Dobbs, K., Bosticardo, M., Reardon, P. K., Lack, J., Ravin, S. S. D., Le, K., Bello, E. A., Pala, F., et al. (2021) · Journal of Clinical Immunology · doi:10.1007/s10875-021-00989-6 · Cited by 43
Soldi, M., Sergi, L. S., Unali, G., Kerzel, T., Cuccovillo, I., Capasso, P., Annoni, A., Biffi, M., Rancoita, P. M. V., Cantore, A., et al. (2020) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2020.10.009 · Cited by 48
Self-citationGene therapy for Fabry disease: Progress, challenges, and outlooks on gene-editing
Domm, J. M., Wootton, S. K., Medin, J. A., & West, M. L. (2021) · Molecular Genetics and Metabolism · doi:10.1016/j.ymgme.2021.07.006 · Cited by 45
CRISPR/Cas9- loxP -Mediated Gene Editing as a Novel Site-Specific Genetic Manipulation Tool
Yang, F., Liu, C., Chen, D., Tu, M., Xie, H., Sun, H., Ge, X., Tang, L., Li, J., Zheng, J., et al. (2017) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2017.04.018 · Cited by 44
CRISPR-Cas9 Gene Editing of Hematopoietic Stem Cells from Patients with Friedreich’s Ataxia
Rocca, C. J., Rainaldi, J., Sharma, J., Shi, Y., Haquang, J. H., Luebeck, J., Mali, P., & Cherqui, S. (2020) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2020.04.018 · Cited by 46
Radtke, S., Pande, D., Cui, M., Perez, A. M., Chan, Y. Y., Enstrom, M., Schmuck, S., Berger, A., Eunson, T., Adair, J. E., et al. (2020) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2020.07.010 · Cited by 42
Novel Genome-Editing Tools to Model and Correct Primary Immunodeficiencies
de Bruin, L. M. O., Volpi, S., & Musunuru, K. (2015) · Frontiers in Immunology · doi:10.3389/fimmu.2015.00250 · Cited by 44
Lee, B., Lozano, R. J., & Dunbar, C. E. (2021) · Molecular Therapy · doi:10.1016/j.ymthe.2021.09.001 · Cited by 39
Bloomer, H., Smith, R. H., Hakami, W., & Larochelle, A. (2020) · Molecular Therapy · doi:10.1016/j.ymthe.2020.12.010 · Cited by 42
Myburgh, R., Ivic, S., Pepper, M. S., Gers-Huber, G., Li, D., Audigé, A., Rochat, M.-A., Jaquet, V., Regenass, S., Manz, M. G., et al. (2015) · Journal of Virology · doi:10.1128/jvi.00277-15 · Cited by 42
Metadata
- Authors
- Genovese, P., Schiroli, G., Escobar, G., Di Tomaso, T., Firrito, C., Calabria, A., Moi, D., Mazzieri, R., Bonini, C., Holmes, M. C., Gregory, P. D., van der Burg, M., Gentner, B., Montini, E., Lombardo, A., & Naldini, L.
- Affiliations
- The San Raffaele Telethon Institute for Gene Therapy (IT)
- Vita-Salute San Raffaele University (IT)
- IRCCS Ospedale San Raffaele (IT)
- Sangamo BioSciences (United States) (US)
- Erasmus MC (NL)
- Corresponding author
- Naldini, Luigi
- ORCID
- Venue
- Nature
- Published
- 2014-05-28
- Volume
- 510
- Issue
- 7504
- Pages
- 235-240
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- PMC
- PMC4082311
- OpenAlex
- W1995497292
- Cited by
- 555
- References
- 44
- Citations by year
- 2026: 7 · 2025: 20 · 2024: 23 · 2023: 32 · 2022: 42 · 2021: 51 · 2020: 43 · 2019: 50 · 2018: 57 · 2017: 57 · 2016: 71 · 2015: 77 · 2014: 24
- FWCI
- 28.82
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature (publishedVersion)
- PubMed (publishedVersion)
- EUR Research Repository (Erasmus University Rotterdam) (publishedVersion)
- PubMed Central (acceptedVersion)
- EUR Research Repository (Erasmus University Rotterdam) (submittedVersion)
- RePub (Erasmus University Rotterdam) (submittedVersion, other-oa)
- RePEc: Research Papers in Economics (submittedVersion)
- Archivio Istituzionale della Ricerca - Università Vita-Salute San Raffaele (submittedVersion)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › CRISPR and Genetic Engineering
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Virus-based gene therapy research
- Health Sciences › Medicine › Hematology › Hematopoietic Stem Cell Transplantation
- Keywords
- targeted genome editing, hematopoietic stem cells, homology-directed repair, gene targeting, IL2RG, X-linked severe combined immunodeficiency, gene therapy, transgene integration
- MeSH terms
- Animals, Endonucleases, Fetal Blood, Hematopoiesis, Hematopoietic Stem Cells, Humans, Male, Mutation, Genome, Human, DNA, Complementary, Hematopoietic Stem Cell Transplantation, Gene Targeting, Antigens, CD34, Mice, Targeted Gene Repair, Interleukin Receptor Common gamma Subunit, X-Linked Combined Immunodeficiency Diseases
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
